Most importantly, our results demonstrate that APG-115-stimulated immunity is able to sensitize resistant tumors to PD-1 blockade into sensitive tumors and such a therapy approach may apply to both Trp53wt and Trp53mut tumors, creating a significant impact because approximately 50% of human cancers are p53 dysfunctional or mutant [41]. Here, TP53 is linked to cancer.